American Regent v. Hikma: Multrys® Patent Dispute Ends in Consent Judgment
American Regent, Inc. filed suit against Hikma Pharmaceuticals USA in the District of New Jersey asserting five patents covering its Multrys® trace elements injection 4* product. The parties resolved the dispute in just 52 days through a consent judgment that includes an injunction — a notably swift and commercially significant resolution in pharmaceutical ANDA litigation.
Five-Patent Multrys® Assertion Yields Injunction in Under Two Months
American Regent, Inc. (ARI), a specialty pharmaceutical company and the holder of five patents covering Multrys® (trace elements injection 4*, USP) in 1 mL single-dose vials, filed this infringement action against Hikma Pharmaceuticals USA, Inc. in the U.S. District Court for the District of New Jersey on 15 August 2025. The case was consolidated with a related action, Civil Action No. 2:25-cv-2224, also brought by ARI against Hikma, indicating a broader assertion strategy across multiple filings targeting Hikma’s anticipated generic entry.
The litigation concluded on 6 October 2025 — just 52 days after filing — through a consent judgment and injunction entered by stipulation of the parties. The consent judgment was agreed for ‘good cause and valuable consideration,’ suggesting a negotiated commercial resolution. Critically, the injunction component means Hikma is formally barred from launching its generic version of Multrys® on terms agreed between the parties, without any court ruling on patent validity or infringement merits.
The 52-day resolution is striking even by the standards of pharmaceutical patent settlements, where many ANDA disputes settle pre-trial but typically after more extensive motion practice. The absence of any invalidity counterclaims proceeding to judgment, combined with a consent injunction, is consistent with Hikma accepting meaningful commercial constraints. The specific terms of the injunction — its duration, any carve-outs, or royalty arrangements — are not disclosed on the public record of this docket.
Filing to Consent Judgment in 52 days
52 days — well below the median ANDA litigation resolution timeline
Consent judgment and injunction: what the agreed resolution means for both parties
Consent judgment combines settlement with binding court order
A consent judgment is not merely a private settlement — it is a court-entered order that carries the full enforcement weight of a judicial ruling. Here, both parties stipulated to its entry, meaning Hikma has accepted binding legal obligations, including an injunction, without the court adjudicating infringement or validity. Breach of a consent judgment can be treated as contempt of court, making it significantly more enforceable than a private settlement agreement alone.
Enforceable as court orderARI secures injunction without litigating validity
American Regent obtained an injunction against Hikma’s generic Multrys® entry without exposing its five patents to invalidity scrutiny in contested proceedings. None of the asserted patents were ruled invalid or narrowed. This preserves ARI’s full patent portfolio in its current form, which may be used in future enforcement actions against other potential generic entrants — a material commercial advantage in the trace elements injection market.
Portfolio preserved intactHikma accepts injunction — generic launch constrained
By consenting to an injunction, Hikma has accepted that its generic version of Multrys® 1 mL single-dose vials cannot be launched under terms it agreed to, without having obtained any judgment of non-infringement or invalidity. The ‘valuable consideration’ language in the stipulation suggests Hikma received commercial concessions, potentially including a future launch date or licensing rights, but these details remain confidential on the public record.
Launch constrained by agreed orderARI’s Multrys® market exclusivity effectively extended by consent
The consent injunction effectively delays or conditions generic competition for Multrys® (trace elements injection 4*, USP), a product used in parenteral nutrition. With five patents intact and an injunction in place, ARI retains strong pricing and market share protection. Other potential generic filers should note that ARI demonstrated willingness and capability to obtain injunctive relief rapidly — within 52 days — signalling a robust enforcement posture for this patent family.
Exclusivity defended in <60 daysFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Specialty pharmaceutical company — holder of US12150956B2 and four related Multrys® patentsSearch in Eureka ↗ |
| Defendant | Hikma Pharmaceuticals USA, Inc. | Company | Generic pharmaceutical manufacturer seeking to market trace elements injection 4* in 1 mL vialsSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated verdict language — ‘resolved this litigation for good cause and valuable consideration’ — is characteristic of a negotiated consent judgment rather than an adversarial merits ruling. No finding of infringement or validity was made by the court. The injunction entered by consent is nonetheless fully enforceable as a court order. The reference to ‘valuable consideration recognised by ARI and HIKMA’ strongly suggests mutual commercial concessions, the specifics of which are not in the public record. The consolidation with Civil Action No. 2:25-cv-2224 indicates ARI treated both cases as a unified enforcement action.
US12150956B2 and four related patents — Multrys® trace elements injection 4*, USP
The five asserted patents — US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2 — collectively protect American Regent’s Multrys® (trace elements injection 4*, USP) product, a parenteral nutrition additive containing essential trace elements including zinc, copper, manganese, and selenium. The patents span multiple application numbers, suggesting a deliberate prosecution strategy to build layered protection across formulation, method, and potentially dosage-form dimensions. Several of these patents carry recent issue dates, indicating a still-active prosecution and portfolio-building effort by ARI.
Multrys® holds significance in the parenteral nutrition market, particularly following FDA guidance emphasising the clinical importance of trace element supplementation in patients on total parenteral nutrition. A five-patent portfolio covering a single 1 mL single-dose vial product reflects a strategy to maximise exclusivity depth. The survival of all five patents through this litigation — without any invalidity ruling — means the portfolio retains its full deterrent and enforcement value against any other generic filer or biosimilar-adjacent competitor working in the parenteral trace elements space.
Should you run an FTO against US12150956B2 and the Multrys® patent family?
Any pharmaceutical company developing, filing an ANDA for, or manufacturing a trace elements injection 4* product in single-dose vial format should treat this five-patent family as a primary FTO priority. The rapid consent injunction in this case demonstrates that ARI actively monitors and enforces this portfolio. Even formulation variations — different vial sizes, concentrations, or excipient profiles — may fall within claim scope depending on the specific claim language of each patent, requiring individual clearance analysis.
PatSnap Eureka’s FTO Search Agent can map all five patents in this family against your product specifications simultaneously, identifying claim-by-claim overlap, prosecution history estoppel, and design-around opportunities. Eureka’s citation network analysis can also identify continuation or divisional applications that may not yet have issued, helping your team anticipate future enforcement risk before an ANDA is filed — not after a complaint lands.
Run a freedom-to-operate analysis on US12150956B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases involving parenteral pharmaceutical formulations
Cases involving parenteral nutrition and injectable formulation patents in the District of New Jersey, where ANDA enforcement actions frequently resolve by consent judgment.
What this case signals for the pharmaceutical trace elements IP landscape
ARI’s rapid consent judgment sets a precedent for aggressive early enforcement of formulation patents in parenteral nutrition products.
Consent injunctions in ANDA cases can be obtained in under 60 days
This case demonstrates that a branded pharmaceutical company with a strong multi-patent portfolio can resolve ANDA litigation — including securing a binding injunction — in under two months. For generic companies, this compresses the window between ANDA filing and meaningful legal exposure. For branded companies, it validates a fast-track enforcement model where settlement leverage is exercised early.
Five-patent stacking amplifies settlement leverage for branded pharma
ARI asserted five patents across two consolidated actions, creating a broad litigation surface that would have required Hikma to mount invalidity and non-infringement arguments on multiple fronts simultaneously. Multi-patent assertion strategies in ANDA cases consistently produce faster and more favorable resolutions for patent holders. Companies in the parenteral pharmaceutical space should audit their own portfolio depth against potential generic entrants.
American v Hikma — key questions answered
The case was resolved by consent judgment and injunction on 6 October 2025, just 52 days after filing. The parties stipulated to entry of a judgment and injunction without any court ruling on patent validity or infringement merits. The specific commercial terms, including any negotiated launch date for Hikma’s generic, are not disclosed on the public docket.
American Regent asserted five patents: US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2. All five cover aspects of the Multrys® (trace elements injection 4*, USP) product in 1 mL single-dose vials. None of the patents were invalidated or narrowed during this litigation.
Under the consent judgment, Hikma is subject to an injunction preventing it from launching its generic version of Multrys® 1 mL single-dose vials on terms agreed with ARI. The stipulation references ‘valuable consideration’ received by both parties, which in ANDA consent judgments typically suggests Hikma received a negotiated future launch date or other commercial concession, though this is not confirmed by the public record.
Yes. The consent judgment references two consolidated actions: Civil Action No. 2:25-cv-14671 (this case) and Civil Action No. 2:25-cv-2224-BRM-CLW, both in the District of New Jersey. Both were initiated by ARI against Hikma and resolved together under the same consent judgment and injunction.
The five patents asserted by ARI — US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2 — all survived this litigation intact. Any generic or biosimilar manufacturer developing a trace elements injection 4* product in single-dose vial format faces a layered patent landscape requiring independent claim-by-claim FTO clearance. ARI’s rapid enforcement posture (consent injunction in 52 days) signals active monitoring of this space.
PatSnap Eureka searches patents and litigation data to answer instantly.